Physician profile
Christopher R Ramirez
NPI 1184076127
$1,165.81
in general payments reported to CMS, 2019-2025
16 companies · $98.86 in 2025
The $98.86 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $16.59 · 2021: $117 · 2022: $287 · 2023: $251 · 2024: $108 · 2025: $98.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $182.11 | 2019-2021 | |
| Biotissue Holdings INC. | $171.15 | 2023-2024 | |
| Rxsight INC | $124.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $122.21 | 2019-2022 | |
| Shire North American Group INC | $121.83 | 2019 | |
| Oyster Point Pharma, INC. | $110.65 | 2023 | Tyrvaya |
| Abbvie INC. | $91.04 | 2022-2025 | |
| Akorn Operating Company LLC | $43.50 | 2021 | |
| Amgen INC. | $39.18 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $35.33 | 2024-2025 | Miebo, Xiidra |
| Ani Pharmaceuticals, INC. | $24.27 | 2022 | |
| Dompe US, INC. | $23.45 | 2022 | |
| Mallinckrodt Hospital Products INC. | $22.57 | 2024 | Acthar |
| Alcon Vision LLC | $19.29 | 2022 | |
| Horizon Therapeutics Plc | $17.65 | 2023 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.